Clinical trial · Observational
The Role of Consolidative Autologous Stem Cell Transplantation After First-line Therapy in Peripheral T Cell Lymphoma
A Prospective Study of Consolidative Autologous Stem Cell Transplantation After First-line Therapy in Peripheral T Cell Lymphoma
NCT04489264CI-TRIAL-00048647unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The role of autologous stem cell transplantation (ASCT) in the first remission (CR1 \& PR1) of peripheral T-cell lymphomas (PTCLs) is not well defined. This study analyzed the impact of ASCT on the clinical outcomes of patients with newly diagnosed PTCL in CR1 and PR1.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Peripheral T Cell Lymphoma | Peripheral T-Cell Lymphoma, Not Otherwise Specified | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Transplant, Autologous | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- ASCT group
- description
- patients who achieved CR or PR after 6-8 cycles first-line therapy receive ASCT as consolidation therapy
- interventionNames
- Drug: Transplant, Autologous
- label
- Observation group
- description
- patients who achieved CR or PR after 6-8 cycles first-line therapy finish their therapy and go into follow-up
Primary outcomes (1)
- measure
- PFS
- timeFrame
- 2-year PFS
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with confirmed pathological diagnosis of aggressive PTCL * Age 18-65 years old * Achieving CR or PR after first-line therapy Exclusion Criteria: * Subtypes with a more indolent course, including precursor T/natural killer neoplasms, T-cell large granular lymphocytic leukemia, mycosis fungoides other than transformed mycosis fungoides, Sézary syndrome, and primary cutaneous CD30-positive disorders.
References
Publications (0)
Data not yet available
No reference posted for this study.